Project Grant R37CA304729
Award Date 8/19/26
Completion Date 7/31/31
Dollars Obligated $726K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Durham, NC 27705, USA
Similar Awards
- The National Cancer Institute awarded Duke University $1.882 million under the Cancer Biology Research program (CFDA 93.396) on September 23, 2025, to integrate genome-wide association study data with single-cell omics to reveal the cellular effectors of glioblastoma predisposition. Work will be performed in Durham, North Carolina, with a completion date of August 31, 2029. The Cancer Biology Research program funds fundamental information on the cause and nature of cancer, encompassing cancer...
- The National Cancer Institute awarded Duke University $509,581 under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2026, to conduct research on innate immune memory for glioma immunotherapy. The research investigates how to enhance the antitumor efficacy of PVSRIPO, a live-attenuated recombinant poliovirus, in patients with recurrent glioblastoma. Clinical trials showed that intratumoral PVSRIPO infusion achieved long-term survival in approximately 20 percent of recurrent...
- The National Institutes of Health National Cancer Institute awarded Massachusetts General Hospital (The General Hospital Corporation) $707,798 on April 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to determine mechanisms of heterogeneous treatment response in glioblastoma using multi-omic and multi-organ approaches. The research identifies transcriptional, genetic, neuronal, and immunological factors influencing glioblastoma formation, progression, and treatment response,...
- The National Cancer Institute awarded Cold Spring Harbor Laboratory $675,617 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate intercellular metabolic and signaling mechanisms of brain cancer-glia communication driving glioblastoma progression. The project examines how glioblastoma cells reprogram brain microglia—the brain's resident immune cells—to create an immunosuppressive tumor microenvironment that promotes tumor growth. The research focuses on an...
- The National Cancer Institute awarded The Research Foundation For The State University Of New York (operating as Stony Brook University) $566,281 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate epigenetic mechanisms underlying the more favorable prognosis of IDH-mutant gliomas compared to glioblastoma. The research examines how isocitrate dehydrogenase (IDH) mutations induce DNA hypermethylation that alters gene regulation and chromatin...
- The National Cancer Institute awarded Duke University $402,135 on May 1, 2026, to develop SCHICAR, a single-cell tri-modal platform that simultaneously captures high-resolution three-dimensional genome interactions (including enhancer-promoter loops), chromatin accessibility, and transcriptomes from individual cells in cancer research. Duke's work addresses a critical limitation in existing single-cell three-dimensional genome methods, which suffer from poor efficiency in capturing long-range...
- The National Cancer Institute awarded Duke University $395,846 on April 1, 2026, as a Project Grant under the Cancer Treatment Research program (CFDA 93.395) to support research on therapeutic targeting of SMARCAL1 in therapy-resistant gliomas through May 31, 2031. The research addresses alternative lengthening of telomeres (ALT), a telomerase-independent mechanism through which 10–15% of cancers achieve replicative immortality. IDH-mutant astrocytomas, characterized by co-occurring mutations in...
- The National Institute of Neurological Disorders and Stroke awarded Georgetown University $429,000 on April 16, 2026, to investigate epigenetic biomarkers in glioblastoma under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The research identifies and characterizes novel epigenetic pathways controlling tumor antigens in glioblastoma, with focus on the polycomb group ring finger 1 (PCGF1) as a regulator of the GD2 CAR T cell antigen....
- The National Cancer Institute awarded the University of North Carolina at Chapel Hill $470,694 on July 2, 2026, to develop a nano electrospun polymeric biomaterial scaffold for glioblastoma interstitial immunotherapy under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The research focuses on engineering acetalated dextran (ACE-DEX), a tunable polymer that can be electrospun into nanofiber scaffolds, to deliver a toll-like receptor 7 & 8 agonist for local immunotherapy at...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded Albert Einstein College of Medicine $431,970 under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2026. The recipient will conduct research into epigenetic regulation of glioblastoma stem-like cells, specifically exploring how the arginine methyltransferase CARM1 controls NGFR and NTRK signaling pathways. The work encompasses two primary aims: testing...